Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report offers an overview of the market trends, drivers, and barriers with respect to the China Plasma Protease C1-inhibitor Treatment market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Plasma Protease C1-inhibitor Treatment market. Detailed analysis of key players, along with key growth strategies adopted by Plasma Protease C1-inhibitor Treatment industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Centogene AG
KalVista Pharmaceuticals, Inc
Takeda Pharmaceutical Company Limited
Ionis Pharmaceuticals, Inc
CSL Behring LLC
BioCryst Pharmaceuticals
Pharming Technologies BV
By Type:
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
By End-User:
Hospital Pharmacies
Independent Pharmacies and Outlets
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Plasma Protease C1-inhibitor Treatment Market
-
1.3 Market Segment by Type
-
1.3.1 China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of C1-inhibitors from 2016 to 2027
-
1.3.2 China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of Kallikrein Inhibitor (Kalbitor) from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of Hospital Pharmacies from 2016 to 2027
-
1.4.2 China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of Independent Pharmacies and Outlets from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Plasma Protease C1-inhibitor Treatment Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Plasma Protease C1-inhibitor Treatment by Major Types
-
3.4.1 Market Size and Growth Rate of C1-inhibitors
-
3.4.2 Market Size and Growth Rate of Kallikrein Inhibitor (Kalbitor)
4 Segmentation of Plasma Protease C1-inhibitor Treatment Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Plasma Protease C1-inhibitor Treatment by Major End-Users
-
4.4.1 Market Size and Growth Rate of Plasma Protease C1-inhibitor Treatment in Hospital Pharmacies
-
4.4.2 Market Size and Growth Rate of Plasma Protease C1-inhibitor Treatment in Independent Pharmacies and Outlets
5 Market Analysis by Regions
-
5.1 China Plasma Protease C1-inhibitor Treatment Production Analysis by Regions
-
5.2 China Plasma Protease C1-inhibitor Treatment Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
6.1 North China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
6.2 North China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
7 Central China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
7.1 Central China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
7.2 Central China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
8 South China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
8.1 South China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
8.2 South China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
9 East China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
9.1 East China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
9.2 East China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
10 Northeast China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
10.1 Northeast China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
10.2 Northeast China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
11 Southwest China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
11.1 Southwest China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
11.2 Southwest China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
12 Northwest China Plasma Protease C1-inhibitor Treatment Landscape Analysis
-
12.1 Northwest China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major Types
-
12.2 Northwest China Plasma Protease C1-inhibitor Treatment Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Centogene AG
-
13.1.1 Centogene AG Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 KalVista Pharmaceuticals, Inc
-
13.2.1 KalVista Pharmaceuticals, Inc Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 Takeda Pharmaceutical Company Limited
-
13.3.1 Takeda Pharmaceutical Company Limited Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Ionis Pharmaceuticals, Inc
-
13.4.1 Ionis Pharmaceuticals, Inc Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 CSL Behring LLC
-
13.5.1 CSL Behring LLC Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 BioCryst Pharmaceuticals
-
13.6.1 BioCryst Pharmaceuticals Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Pharming Technologies BV
-
13.7.1 Pharming Technologies BV Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of C1-inhibitors from 2016 to 2027
-
Figure China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of Kallikrein Inhibitor (Kalbitor) from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of Hospital Pharmacies from 2016 to 2027
-
Figure China Plasma Protease C1-inhibitor Treatment Market Size and Growth Rate of Independent Pharmacies and Outlets from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Plasma Protease C1-inhibitor Treatment Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Plasma Protease C1-inhibitor Treatment
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Plasma Protease C1-inhibitor Treatment by Different Types from 2016 to 2027
-
Table Consumption Share of Plasma Protease C1-inhibitor Treatment by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of C1-inhibitors
-
Figure Market Size and Growth Rate of Kallikrein Inhibitor (Kalbitor)
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Plasma Protease C1-inhibitor Treatment by Different End-Users from 2016 to 2027
-
Table Consumption Share of Plasma Protease C1-inhibitor Treatment by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospital Pharmacies
-
Figure Market Size and Growth Rate of Independent Pharmacies and Outlets
-
Table China Plasma Protease C1-inhibitor Treatment Production by Regions
-
Table China Plasma Protease C1-inhibitor Treatment Production Share by Regions
-
Figure China Plasma Protease C1-inhibitor Treatment Production Share by Regions in 2016
-
Figure China Plasma Protease C1-inhibitor Treatment Production Share by Regions in 2021
-
Figure China Plasma Protease C1-inhibitor Treatment Production Share by Regions in 2027
-
Table China Plasma Protease C1-inhibitor Treatment Consumption by Regions
-
Table China Plasma Protease C1-inhibitor Treatment Consumption Share by Regions
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption Share by Regions in 2016
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption Share by Regions in 2021
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption Share by Regions in 2027
-
Table North China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table North China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table North China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table North China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure North China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table Central China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table Central China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table Central China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table Central China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure Central China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table South China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table South China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table South China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table South China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure South China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table East China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table East China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table East China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table East China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure East China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table Northeast China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table Northeast China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure Northeast China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table Southwest China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table Southwest China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure Southwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table Northwest China Plasma Protease C1-inhibitor Treatment Consumption by Types from 2016 to 2027
-
Table Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2016
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2021
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by Types in 2027
-
Table Northwest China Plasma Protease C1-inhibitor Treatment Consumption by End-Users from 2016 to 2027
-
Table Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2016
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2021
-
Figure Northwest China Plasma Protease C1-inhibitor Treatment Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Centogene AG
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Centogene AG
-
Figure Sales and Growth Rate Analysis of Centogene AG
-
Figure Revenue and Market Share Analysis of Centogene AG
-
Table Product and Service Introduction of Centogene AG
-
Table Company Profile and Development Status of KalVista Pharmaceuticals, Inc
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of KalVista Pharmaceuticals, Inc
-
Figure Sales and Growth Rate Analysis of KalVista Pharmaceuticals, Inc
-
Figure Revenue and Market Share Analysis of KalVista Pharmaceuticals, Inc
-
Table Product and Service Introduction of KalVista Pharmaceuticals, Inc
-
Table Company Profile and Development Status of Takeda Pharmaceutical Company Limited
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceutical Company Limited
-
Figure Sales and Growth Rate Analysis of Takeda Pharmaceutical Company Limited
-
Figure Revenue and Market Share Analysis of Takeda Pharmaceutical Company Limited
-
Table Product and Service Introduction of Takeda Pharmaceutical Company Limited
-
Table Company Profile and Development Status of Ionis Pharmaceuticals, Inc
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ionis Pharmaceuticals, Inc
-
Figure Sales and Growth Rate Analysis of Ionis Pharmaceuticals, Inc
-
Figure Revenue and Market Share Analysis of Ionis Pharmaceuticals, Inc
-
Table Product and Service Introduction of Ionis Pharmaceuticals, Inc
-
Table Company Profile and Development Status of CSL Behring LLC
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of CSL Behring LLC
-
Figure Sales and Growth Rate Analysis of CSL Behring LLC
-
Figure Revenue and Market Share Analysis of CSL Behring LLC
-
Table Product and Service Introduction of CSL Behring LLC
-
Table Company Profile and Development Status of BioCryst Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of BioCryst Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of BioCryst Pharmaceuticals
-
Figure Revenue and Market Share Analysis of BioCryst Pharmaceuticals
-
Table Product and Service Introduction of BioCryst Pharmaceuticals
-
Table Company Profile and Development Status of Pharming Technologies BV
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pharming Technologies BV
-
Figure Sales and Growth Rate Analysis of Pharming Technologies BV
-
Figure Revenue and Market Share Analysis of Pharming Technologies BV
-
Table Product and Service Introduction of Pharming Technologies BV
-
